Please check your internet connection and try again.
# Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep
## Overview
Tebentafusp is a bispecific fusion protein that targets the tumor-associated antigen gp100 and the T cell receptor, stimulating an immune response against melanoma cells expressing gp100.
## Primary Indications
Unresectable or metastatic uveal melanoma in HLA-A\*02:01-positive adult patients.
## Adult Dosing
Administer via intravenous infusion.
* **Initial dose:** 20 mcg (0.02 mg) on Day 1.
* **Second dose:** 70 mcg (0.07 mg) on Day 8.
* **Subsequent doses:** 100 mcg (0.1 mg) on Day 15, and every 3 weeks thereafter.
* **Infusion rate:** Start at 10 mL/hr and increase gradually to a maximum of 200 mL/hr, as tolerated.
## Pediatric Dosing
No established pediatric dosing. Safety and efficacy have not been studied in this population.
## Dose Adjustments
Dose adjustments may be required due to adverse reactions, particularly immune-related toxicities. Refer to the prescribing information for specific guidance on dose interruption and reduction.
## Contraindications
* Known hypersensitivity to tebentafusp or any component of its formulation.
## Adverse Effects
Common adverse effects (≥20%) include rash, pyrexia, pruritus, musculoskeletal pain, fatigue, nausea, edema, abdominal pain, headache, hypertension, chills, and dry skin. Serious adverse effects include immune-related toxicities (e.g., uveitis, dermatitis, colitis, hepatitis, endocrinopathies) and infusion reactions.
## Key Drug Interactions
No significant drug interactions have been identified. However, caution is advised when co-administering with other immunomodulatory agents.
## Monitoring
* Monitor for signs and symptoms of immune-related adverse events (irAEs), especially ocular toxicity (e.g., vision changes, eye pain).
* Monitor vital signs during and after infusion for infusion reactions.
* Monitor liver function tests, as hepatitis can occur.
* Monitor for signs of endocrinopathies.
## Clinical Pearls
* HLA-A\*02:01 typing is required prior to initiating therapy.
* Patients should be educated on the signs and symptoms of irAEs and instructed to report them promptly.
* Consider prophylactic treatment for irAEs based on clinical judgment and local protocols.
* Ocular adverse events, particularly uveitis, are a significant concern and require prompt ophthalmologic evaluation and management.
***
**Disclaimer:** This information is intended for clinical decision-making and does not replace professional medical judgment. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions.
